Eli Lilly and Company (NYSE:LLY) is Jeppson Wealth Management LLC’s 9th Largest Position

Jeppson Wealth Management LLC trimmed its position in shares of Eli Lilly and Company (NYSE:LLY) by 3.8% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 5,437 shares of the company’s stock after selling 214 shares during the quarter. Eli Lilly and Company makes up 1.9% of Jeppson Wealth Management LLC’s portfolio, making the stock its 9th biggest holding. Jeppson Wealth Management LLC’s holdings in Eli Lilly and Company were worth $4,923,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Tidemark LLC purchased a new stake in shares of Eli Lilly and Company in the 4th quarter worth about $29,000. Core Wealth Advisors Inc. raised its position in Eli Lilly and Company by 188.2% during the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after acquiring an additional 32 shares during the last quarter. Lynx Investment Advisory purchased a new stake in shares of Eli Lilly and Company in the second quarter valued at about $32,000. LGT Financial Advisors LLC acquired a new stake in shares of Eli Lilly and Company in the second quarter valued at approximately $36,000. Finally, Frank Rimerman Advisors LLC purchased a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $37,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Transactions at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of Eli Lilly and Company stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the transaction, the insider now owns 96,943,810 shares in the company, valued at approximately $91,109,731,514.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 737,410 shares of company stock valued at $669,719,100 over the last 90 days. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Up 0.6 %

Shares of LLY opened at $918.25 on Friday. Eli Lilly and Company has a twelve month low of $516.57 and a twelve month high of $972.53. The firm has a market capitalization of $872.71 billion, a P/E ratio of 134.43, a price-to-earnings-growth ratio of 2.91 and a beta of 0.41. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. The stock’s fifty day simple moving average is $896.03 and its 200 day simple moving average is $826.65.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The company had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. On average, equities research analysts forecast that Eli Lilly and Company will post 16.51 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 annualized dividend and a yield of 0.57%. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Analyst Ratings Changes

LLY has been the topic of a number of recent research reports. Guggenheim upped their target price on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Jefferies Financial Group increased their price objective on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research note on Monday, June 24th. BMO Capital Markets boosted their target price on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Deutsche Bank Aktiengesellschaft raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and raised their price target for the stock from $725.00 to $1,025.00 in a research note on Monday, August 12th. Finally, Argus boosted their price objective on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a research report on Tuesday, May 14th. Two research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average target price of $961.76.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.